Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Current Deferred Revenue (2010 - 2017)

Nephros' quarterly Current Deferred Revenue came in at $70000.0 in Q4 2017, down 69.16% year-on-year from $227000.0 in Q4 2016, and little changed quarter-over-quarter from $70000.0 in Q3 2017.

Nephros has reported Current Deferred Revenue for 8 years, with the latest figure at $70000.0 in Q4 2017.

  • For the quarter ending Q4 2017, Current Deferred Revenue fell 69.16% year-over-year to $70000.0; the trailing twelve-month figure through Dec 2017 stood at $70000.0 (down 69.16% YoY), and the FY2017 full-year result was $70000.0, down 69.16% from the prior year.
  • Current Deferred Revenue for Q4 2017 stood at $70000.0, roughly flat from $70000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $873000.0 in Q2 2014, with the low at $70000.0 in Q1 2015.
  • Average Current Deferred Revenue over 5 years is $283600.0, with a median of $70000.0 recorded in 2015.
  • Year-over-year, Current Deferred Revenue plunged 91.98% in 2015 and soared 224.29% in 2016.
  • Tracing NEPH's Current Deferred Revenue over 5 years: stood at $703000.0 in 2013, then tumbled by 30.73% to $487000.0 in 2014, then tumbled by 85.63% to $70000.0 in 2015, then soared by 224.29% to $227000.0 in 2016, then plunged by 69.16% to $70000.0 in 2017.
  • The last three Current Deferred Revenue figures came in at $70000.0 (Q4 2017), $70000.0 (Q3 2017), and $70000.0 (Q2 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Nephros 38.93 Mn 34.91 Mn 2.99 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2017 70,000.00
Sep 30, 2017 70,000.00
Jun 30, 2017 70,000.00
Mar 31, 2017 70,000.00
Dec 31, 2016 227,000.00
Sep 30, 2016 70,000.00
Jun 30, 2016 70,000.00
Mar 31, 2016 70,000.00
Dec 31, 2015 70,000.00
Sep 30, 2015 70,000.00
Jun 30, 2015 70,000.00
Mar 31, 2015 70,000.00
Dec 31, 2014 487,000.00
Sep 30, 2014 245,000.00
Jun 30, 2014 873,000.00
Mar 31, 2014 254,000.00
Dec 31, 2013 703,000.00
Sep 30, 2013 702,000.00
Jun 30, 2013 703,000.00
Mar 31, 2013 708,000.00
Dec 31, 2012 707,000.00
Sep 30, 2012 704,000.00
Jun 30, 2012 674,000.00
Mar 31, 2012 699,000.00
Dec 31, 2011 2.09 Mn
Sep 30, 2011 500,000.00
Dec 31, 2010 33,000.00